Impact of Yondeli (TM) (trabectedin, ET-743) in the natural history of patients (pts) with pretreated advanced soft tissue sarcomas (PASTS): Long term follow-up results.

A Lecesne, G Demetri, JL Misset, J Blay, I Judson, A Yovine, A Van Oosterom, J Radford, J Verweij, R Maki, E Brain, P Herait, MA Izquierdo, J Gomez, A Nieto, J Saro, J Jimeno

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageUndefined
Pages (from-to)6076S-6076S
Number of pages11
JournalClinical Cancer Research
Volume9
Issue number16 Suppl 5 Part 2
Publication statusPublished - 1 Dec 2003

Cite this